B I O S C I E N C E S , I N C .
Congress did their part by expanding
reimbursement for non-opioid
postsurgical options. Now it's your turn:
Learn more about the NOPAIN Act's mandate that Medicare provide
ASP+6% reimbursement for qualifying non-opioid options in
outpatient surgeries
1,2
Make a pact to support the Act, which goes into e ect January 1, 2025
References:
1. Congress.gov. One hundred seventeenth congress of the United States of America. Accessed June 12, 2024. https://www.congress.gov/117/
bills/hr2617/BILLS-117hr2617enr.pdf
2. CMS.gov. Medicare part B drug average sales price. Updated April 2, 2024. Accessed June 12, 2024. https://www.cms.gov/medicare/payment/
fee-for-service-providers/part-b-drugs/average-drug-sales-price
ASP, average sales price; ASP+6 = reimbursement of 106% of the average sales price; NOPAIN Act, Non-Opioids Prevent Addiction in the Nation Act.
© 2024 Pacira Pharmaceuticals, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. All rights reserved. PP-NP-1617 07/2024
VISIT
NOPAINPact.com
TO TAKE
ACTION.
